Loading clinical trials...

UNKNOWNNA

Application of hybridAPC in the Treatment of Barrett

Application of hybridAPC in the Treatment of Barrett: a Multicenter, Prospective Study

NCT03418584•Changhai Hospital

Summary

The purpose of this study is to evaluate the efficacy and safety of the new technique of HybridAPC in the treatment of Barrett.

Detailed Description

After thermal ablation of Barrett's esophagus, stricture formation is reported in 5 to over 10% of patients. Submucosal fluid injection prior to ablation may lower the risk of stricture formation. The new technique of HybridAPC which combines submucosal injection with APC is considered to reduce the complication.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Patients age is from 18 to 70.
•2. Patients who were diagnosed with Barrett's esophagus.
•3. Informed consent.

Exclusion Criteria

•1. Patient with severe cardiopulmonary dysfunction is unable to tolerated by endoscopy.
•2. Severe bleeding tendency.
•3. Poor compliance.
•4. Patient is very ill and life expectancy is less than 2 years.
•5. Esophageal varices or venous aneurysms, and no effective prevention or treatment for bleeding.
•6. Severe esophageal stenosis.
•7. Pregnancy.
•8. Lesion is located in esophageal diverticulum or spread their diverticulum.

Locations (1)

Department of Gastroenterology, Changhai Hospital, Second Military Medical University

Shanghai, Shanghai Municipality, China

Key Dates

Start Date

December 5, 2017

Primary Completion Date

December 5, 2020

Completion Date

December 5, 2021

Last Updated

February 1, 2018

Enrollment

ESTIMATED participants

Conditions

Barrett's Esophagus

Interventions

HybridAPC

DEVICE

Contacts

Dong Wang, M.D

CONTACT

8613816758802 dongwang0901@sina.com

Zhijie Wang, M.D

CONTACT

8613816758802 wangzhijie0708@163.com

A Study of Barrett's Esophagus Patients to Investigate Quality of Life and Fear of Cancer, and Optimize a Risk Model Based on Biomarkers and New Technologies to Better Predict the Development of Cancer

NCT06523374

Barrett's EsophagusEsophageal Adenocarcinoma

View study

RECRUITING

Australian Barrett's Cohort With Dysplasia and Early Cancer Study

NCT02198976

Barrett's Esophagus

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 1, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Application of hybridAPC in the Treatment of Barrett

Inclusion Criteria

Exclusion Criteria

A Study of Barrett's Esophagus Patients to Investigate Quality of Life and Fear of Cancer, and Optimize a Risk Model Based on Biomarkers and New Technologies to Better Predict the Development of Cancer

Australian Barrett's Cohort With Dysplasia and Early Cancer Study

Barrett's Esophagus Related Neoplasia (BERN) Project

CBAS180 De-escalation Study

Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus and the Creation of a Barrett's Registry

Cell Marker Predictors in Barrett's Esophagus